Psilocybin Therapy for Treatment-Resistant Depression is Being Taken Seriously by Regulators as FDA Gives Go-Ahead to Clinical Trial

Psilocybin, the psychoactive compound in hallucinogenic “magic mushrooms,” is emerging as a potential treatment for mental health disorders, however researchers have limited data on the safety and effectiveness of the drug for this indication. Now, London, England-based life sciences company COMPASS Pathways has announced it will be initiating a clinical trial of psilocybin in patients with treatment-resistant depression.